Collectively, these analyses suggest that the mesolimbic reward system may be more potently engaged with GLP-1MK-801 than semaglutide treatment
J Control Release 351:504559
Diabetes 52 , 356364 (2003)
Austin, TX No waiting rooms, no awkward appointments
Eligibility criteria for non-diabetic tirzepatide use typically include a BMI of 30 kg/m or higher, or a BMI of 27 kg/m or higher with at least one weight-related health condition (such as hypertension, sleep apnea, or cardiovascular disease)
Personalizing Treatment Based on DEXA Results Healthcare providers can use DEXA scan data to tailor GLP-1 treatment plans, including dietary, exercise, or medication adjustments to optimize body composition outcomes